SCOTT JOSEPH COOLE D.O.
Prescription History 1497744577
Internal Medicine - Pulmonary Disease in Lake Havasu City, AZ


Quality Rating: 83.23 out of 100 score

NPI Status: Active since October 20, 2005

Contact Information

1851 MESQUITE AVE STE 210
LAKE HAVASU CITY, AZ
ZIP 86403
Phone: (928) 854-7540
Fax: (928) 854-2505

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for SCOTT JOSEPH COOLE D.O., an active Pulmonary Disease specialist practicing in Lake Havasu City, AZ. Our medical registry currently tracks 5 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 150 documented patient claims. Among these therapy options, the most frequently utilized medication is Trelegy Ellipta, which accounts for 68 claims alone.

Medication Index

No matching medications currently found on file.

Albuterol Sulfate Hfa

Generic Formulation: Albuterol SulfateSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 42
30-Day Fills 88.1
Days Supply 2,547
AZ State Average Benchmarks
Peer Average Claims53.0
Peer Average 30-Day Fills67.5
Peer Average Days Supply1,674
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across AZ. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $2,652.93 across this reporting matrix range.

Provider Avg Cost Per Claim

$63.17

State Avg Cost Per Claim

$48.73

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A short-acting beta-2 adrenergic agonist that is primarily used as a bronchodilator agent to treat ASTHMA. Albuterol is prepared as a racemic mixture of R(-) and S(+) stereoisomers. The stereospecific preparation of R(-) isomer of albuterol is referred to as levalbuterol.

Therapeutic Applications

Albuterol (also known as salbutamol) is used to treat wheezing and shortness of breath caused by breathing problems such as asthma. It is a quick-relief medication. Albuterol belongs to a class of drugs known as bronchodilators. It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Controlling symptoms of breathing problems can decrease time lost from work or school.

Eliquis

Generic Formulation: ApixabanSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 12
30-Day Fills 12.0
Days Supply 360
AZ State Average Benchmarks
Peer Average Claims70.0
Peer Average 30-Day Fills126.3
Peer Average Days Supply3,676
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 82.9% less volume than the regional standard for practitioners inside AZ. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $7,205.00 across this reporting matrix range.

Provider Avg Cost Per Claim

$600.42

State Avg Cost Per Claim

$954.67

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Apixaban is used to prevent serious blood clots from forming due to a certain irregular heartbeat (atrial fibrillation) or after hip/knee replacement surgery. With atrial fibrillation, part of the heart does not beat the way it should. This can lead to blood clots forming, which can travel to other parts of your body (such as the lungs or legs) or increase your risk for stroke. In the United States, apixaban is also approved to treat certain types of blood clots (deep vein thrombosis-DVT, pulmonary embolus-PE) and to prevent them from forming again. Apixaban is an anticoagulant that works by blocking certain clotting proteins in your blood.

Prednisone

Generic Formulation: PrednisoneSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 17
30-Day Fills 27.0
Days Supply 763
AZ State Average Benchmarks
Peer Average Claims44.0
Peer Average 30-Day Fills55.1
Peer Average Days Supply1,030
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 61.4% less volume than the regional standard for practitioners inside AZ. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $170.20 across this reporting matrix range.

Provider Avg Cost Per Claim

$10.01

State Avg Cost Per Claim

$6.21

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.

Therapeutic Applications

Prednisone is used to treat conditions such as arthritis, blood disorders, breathing problems, severe allergies, skin diseases, cancer, eye problems, and immune system disorders. Prednisone belongs to a class of drugs known as corticosteroids. It decreases your immune system's response to various diseases to reduce symptoms such as swelling and allergic-type reactions.

Trelegy Ellipta

Generic Formulation: Fluticasone/Umeclidin/VilanterSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 68
30-Day Fills 132.0
Days Supply 3,960
AZ State Average Benchmarks
Peer Average Claims57.0
Peer Average 30-Day Fills80.6
Peer Average Days Supply2,414
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across AZ. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $86,348.57 across this reporting matrix range.

Provider Avg Cost Per Claim

$1,269.83

State Avg Cost Per Claim

$909.86

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product is used to control and prevent symptoms (such as wheezing and shortness of breath) caused by asthma and ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes chronic bronchitis and emphysema). Controlling symptoms of breathing problems helps you stay active. This inhaler contains 3 medications: fluticasone, umeclidinium, and vilanterol. Fluticasone belongs to a class of drugs known as corticosteroids. It works by reducing swelling of the airways in the lungs to make breathing easier. Umeclidinium belongs to a class of drugs known as anticholinergics and vilanterol is a LABA medication. Both drugs work by relaxing the muscles around the airways so that they open up and you can breathe more easily. Both drugs are also known as bronchodilators. When used alone, long-acting beta agonists (such as vilanterol) may rarely increase the risk of serious (sometimes fatal) asthma-related breathing problems. However, combination products containing both an inhaled corticosteroid and long-acting beta agonist, such as this product, do not increase the risk of serious asthma-related breathing problems. For asthma treatment, this product should be used when breathing problems are not well controlled with two asthma-control medications (such as inhaled corticosteroid and long-acting beta agonist) or if your symptoms need combination treatment. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden shortness of breath. If sudden breathing problems occur, use your quick-relief inhaler as prescribed.

Xarelto

Generic Formulation: RivaroxabanSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 11
30-Day Fills 11.0
Days Supply 330
AZ State Average Benchmarks
Peer Average Claims40.0
Peer Average 30-Day Fills81.1
Peer Average Days Supply2,382
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 72.5% less volume than the regional standard for practitioners inside AZ. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $6,891.67 across this reporting matrix range.

Provider Avg Cost Per Claim

$626.52

State Avg Cost Per Claim

$1,063.10

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A morpholine and thiophene derivative that functions as a FACTOR XA INHIBITOR and is used in the treatment and prevention of DEEP-VEIN THROMBOSIS and PULMONARY EMBOLISM. It is also used for the prevention of STROKE and systemic embolization in patients with non-valvular ATRIAL FIBRILLATION, and for the prevention of atherothrombotic events in patients after an ACUTE CORONARY SYNDROME.

Therapeutic Applications

Rivaroxaban is used to prevent blood clots from forming due to a certain irregular heartbeat (atrial fibrillation) or after hip or knee replacement surgery. It is also used to prevent blood clots from forming in high-risk patients with limited mobility during their hospital stay and after discharge. In addition, rivaroxaban is used to treat blood clots (such as in deep vein thrombosis-DVT or pulmonary embolus-PE) and to prevent the blood clots from forming again. Rivaroxaban may be used in children to prevent blood clots from forming after a certain heart surgery (Fontan procedure). Rivaroxaban is an anticoagulant that works by blocking certain clotting proteins in your blood.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like SCOTT JOSEPH COOLE D.O. provides transparency into local medical care patterns within Lake Havasu City, AZ.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Pulmonary Disease** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.